Globenewswire·2026-03-04 08:30Core Insights - HUTCHMED has initiated a Phase I/IIa clinical trial for HMPL-A580, its second Antibody-Targeted Therapy Conjugate (ATTC), targeting unresectable, advanced, or metastatic solid tumors in China and the US, with the first patient dosed on March 4, 2026 [1] Group 1: Product Overview - HMPL-A580 is a first-in-class ATTC that combines a selective PI3K/PIKK small-molecule inhibitor with an anti-EGFR antibody, designed to enhance anti-tumor activity through simultaneous inhibition of the PAM pathway and EGFR signaling [2][8] - The ATTC platform represents a next-generation approach to precision oncology, aiming to achieve synergistic anti-tumor activity and improved safety compared to traditional cytotoxin-based therapies [4][5] Group 2: Clinical Trial Details - The Phase I/IIa study is a multicenter, open-label trial assessing the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of HMPL-A580, consisting of a dose escalation phase followed by a dose expansion phase [3] - The trial aims to determine the maximum tolerated dose and recommended dose for further development in selected solid tumors [3] Group 3: Mechanism of Action - The PAM pathway is critical for cell growth and survival, and its alterations are linked to poor prognosis in various cancers; HMPL-A580 aims to deliver targeted inhibition directly to EGFR-expressing tumor cells, potentially overcoming systemic toxicity associated with existing PAM-targeted therapies [7][8]